on VALBIOTIS (EPA:ALVAL)
Valbiotis Expands Product Range with Menopause Solution
Valbiotis SA, a French laboratory, has launched ValbiotisPLUS® Menopause & Perimenopause, a new addition to their dietary supplement line. This product, available from February 3, aims to support women's health during menopause and perimenopause. The ValbiotisPLUS® range focuses on cardio-metabolic balance, expanding to eleven products, including the new menopause supplement.
The latest addition comes amid growing demand for menopause-related health products, with French pharmacy sales hitting €21.4 million in 2024. Valbiotis leverages scientific literature for a hormone-free solution, emphasizing a comprehensive metabolic health approach.
Valbiotis plans a marketing push targeting both pharmacy and e-commerce channels to maximize reach. Shareholders benefit from a 20% discount on the product range. The launch highlights Valbiotis' commitment to addressing significant health issues with natural ingredients and scientific backing.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news